Similar articles

• [Sodium di-n-propylacetate: evaluation of its so-called psychotropic effect. A controlled study].

  Sommerbeck KW, Theilgaard A, Rasmussen KE, Løhren V, Gram L, Wulff K. Sommerbeck KW, et al. Ugeskr Laeger. 1977 May 2;139(18):1069-73. Ugeskr Laeger. 1977. PMID: 324059 Clinical Trial. Danish. No abstract available.
• [Clinical--pharmacological aspects of treatment with sodium di-n-propylacetate].

  Wulff K, Flachs H, Würtz-Jørgensen A, Gram L. Wulff K, et al. Ugeskr Laeger. 1977 May 2;139(18):1059-64. Ugeskr Laeger. 1977. PMID: 324057 Clinical Trial. Danish. No abstract available.
• [Treatment of pyknoleptic petit mal epilepsy and juvenile myoclonic epilepsy with dipropyl acetate (Deprakine). A pilot study of therapy-resistant patients during control of plasma concentration].

  Schroll M, Naestoft J, Lund M. Schroll M, et al. Ugeskr Laeger. 1977 May 2;139(18):1073-7. Ugeskr Laeger. 1977. PMID: 404744 Clinical Trial. Danish. No abstract available.
• Sodium di-N-propylacetate (DPA) in the treatment of epilepsy. A review.

  Simon D, Penry JK. Simon D, et al. Epilepsia. 1975 Nov;16(4):549-73. doi: 10.1111/j.1528-1157.1975.tb04738.x. Epilepsia. 1975. PMID: 812693 Review.
• [Valproic acid in the treatment of epilepsy with special emphasis on serum level determination (author's transl)].

  Fröscher W, Schulz HU, Gugler R. Fröscher W, et al. Fortschr Neurol Psychiatr Grenzgeb. 1978 Jun;46(6):327-41. Fortschr Neurol Psychiatr Grenzgeb. 1978. PMID: 352872 Review. German.